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Abstract 
 
Several genetic, neurodevelopmental and pharmacological animal models of 
schizophrenia have been established. This short review examines the validity of 
one of the most used pharmacological model of the illness, i.e the acute 
administration of NMDA receptor antagonists in rodents. In some cases, data 
on chronic or prenatal NMDA receptor antagonist exposure have been 
introduced for comparison. The face validity of acute NMDA receptor blockade 
is granted inasmuch as hyperlocomotion and stereotypies induced by 
phencyclidine, ketamine and MK-801 are regarded as a surrogate for the 
positive symptoms of schizophrenia. In addition, the loss of parvalbumin-
containing cells (which is one of the most compelling finding in postmortem 
schizophrenia brain) following NMDA receptor blockade, adds construct validity 
to this model. However, the lack of changes in GAD67 is at variance with human 
studies. It is possible that changes in GAD67 are more reflective of the 
neurodevelopmental condition of schizophrenia. Finally, the model also has 
predictive validity in that its behavioral and transmitter activation in rodents are 
responsive to antipsychotic treatment. Overall, although not devoid of 
drawbacks, the acute administration of NMDA receptor antagonists can be 
considered as a good model of schizophrenia bearing a satisfactory degree of 
validity. 
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Clinical evidence of NMDA hypofunction in schizophrenia 
Psychiatric illnesses can be considered as uniquely human in that 1) they affect 
complex, higher brain functions, and 2) their diagnostic is usually carried out by 
structured interviews following standardized procedures, which obviously 
cannot be reproduced in animals. Therefore, animal models of psychiatric 
disorders face the main difficulty of replicating in the animal brain the alterations 
that are presumed to occur in the human brain. However, animal models are a 
crucial tool to study these changes inasmuch as the animal brain can be 
accessed directly. 
 The hypothesis of N-methyl-D-aspartate (NMDA) receptor hypofunction 
in schizophrenia stemmed from the clinical observation that a single 
subanesthetic dose of noncompetitive NMDA antagonists, such as 
phencyclidine (PCP) and ketamine, induced in healthy individuals psychotic and 
negative symptoms, as well as cognitive impairment, that resemble those 
present in schizophrenia1,2. The present review will address the advantages and 
limitations of using NMDA receptor antagonists to model schizophrenia by 
comparing their actions in the clinical and preclinical settings. 
 Postmortem studies have shown alterations of subunit expression as well 
as trafficking complex and intracellular signaling proteins of NMDA receptors in 
prefrontal cortex of subjects with schizophrenia3. Further, recent imaging 
studies using a novel SPECT tracer for the NMDA receptor have reported the 
first in vivo evidence of a NMDA receptor reduction in medication-free 
schizophrenic patients4. Besides, ketamine also induced a reduction of NMDA 
receptors in the human brain, which strongly correlated with the scores of 
negative symptoms5. 
 An important issue to be considered herein is the difference between 
acute and chronic dosage of NMDA antagonists. As reviewed by Jentsch and 
Roth6, repeated use of PCP leads to a more persistent schizophrenic 
symptomatology. As a result, these authors propose that sustained exposure to 
PCP may better simulate the chronic symptoms of schizophrenia such as the 
negative symptoms and cognitive deficits. In contrast, an acute regimen would 
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rather resemble first episode schizophrenia. Altogether, from a clinical 
viewpoint, the NMDA hypofunction model of schizophrenia possesses strong 
similarities in several major symptoms with schizophrenia. Indeed, PCP and 
ketamine recreate the symptoms of schizophrenia more accurately than do 
other psychotomimetic drugs, such as amphetamine or LSD. 
 
NMDA antagonism-induced sensory gating changes in humans 
Deficits in information-processing have become the focus of interest because of 
their relevance in the functional impairment experienced by schizophrenic 
patients. Abnormalities in the cortico-striato-thalamo-cortical circuitry may 
account for such deficits. Thus, thalamic gating deficits would result in a 
sensory overload of cortical structures and the subsequent cognitive deficiency. 
Schizophrenic patients exhibit robust deficits in sensory gating processes that 
can be measured in different paradigms such as reductions of the prepulse 
inhibition (PPI) of the acoustic startle reflex7 and deficits in mismatch negativity8. 
Reductions of mismatch negativity were noticed also following acute ketamine 
administration to healthy subjects9. However, the administration of ketamine to 
healthy volunteers showed no change or an increase in PPI10, which is in 
contrast to the effects consistently observed in rodents (see below). 
 
Comparison with preclinical studies 
Behavioral studies 
In rodents, systemic administration of NMDA antagonists induces 
hyperlocomotion and stereotypies, behaviors that are potentially related to 
positive symptoms of schizophrenia, and are often associated with elevated 
dopaminergic and serotonergic tones. NMDA receptor antagonists also produce 
disruptions in PPI and deficits in different domains of cognition, features that 
have relevance to impairment of cognitive symptoms consistently observed in 
schizophrenia. As mentioned above, NMDA receptor antagonist-induced deficits 
in PPI in rodents contrast with reports in humans in which NMDA antagonists 
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fail to decrease PPI. In accordance with human studies, however, NMDA 
receptor antagonists block the generation of mismatch negativity in monkeys11. 
 
Neurochemical and neurophysiological studies 
Acute NMDA receptor antagonism induces an excessive prefrontal activity 
measured as increased firing rate of pyramidal neurons and expression of c-fos 
mRNA. As a consequence, there are also increases in the release of cortical 
transmitters such as glutamate, dopamine and serotonin (5-HT)12,13. These 
facilitatory effects likely result from enhanced excitatory glutamatergic inputs 
onto midbrain dopamine and 5-HT cell groups arising from the prefrontal cortex. 
Although no direct measure of brain glutamate release exists for the brain of 
schizophrenics, some studies have evidenced activation of prefrontal cortex in 
first-episode schizophrenia14,15, and after ketamine administration16, which is 
suggestive of increased glutamate release in humans. In contrast, hypofrontality 
seems to be prominent in chronic schizophrenia and has been consistently 
observed following long-term exposure to NMDA receptor antagonists6. 
 In line with the increased dopaminergic transmission in rodents, PET 
imaging studies in humans have consistently evidenced an increased release of 
dopamine in striatum in schizophrenia. In addition, the administration of 
ketamine to healthy subjects has been shown to increase the release of 
dopamine in ventral striatum, which strongly correlated with the appearance of 
psychotic symptoms17. No similar abundance of results has been reported for 
serotonergic systems. A few studies with unmedicated patients, however, have 
reported diminished density of 5-HT2A receptors in schizophrenia that could 
result from a compensatory response to an excessive release of endogenous 5-
HT18. 
 At first sight, it may seem paradoxical that the blockade of an excitatory 
glutamatergic receptor results in a multitude of such facilitatory actions. Based 
fundamentally on an accumulating body of results using experimental animals, it 
has been proposed that the array of effects of NMDA antagonists arises from 
their preferential blockade of NMDA receptors localized to GABAergic neurons 
of corticolimbic circuits, thus disrupting cortical inhibition and resulting in a 
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disinhibition of glutamatergic (pyramidal) neurons, which is associated with 
excessive neuronal activity19. In good accordance with this view, it has been 
demonstrated that two consecutive injections of ketamine reduced activity in 
cortical interneurons via activation of immune processes20. Interestingly, the 
acute administration of NMDA antagonists results in a decrease of GABA 
release in the prefrontal cortex and the reduction of prefrontal GABA activity has 
been shown to induce cognitive, behavioral, and dopaminergic alterations that 
resemble those of schizophrenia21. It is important to note that caution must be 
taken when using the terms hypo- or hyperglutamatergia with reference to 
changes in glutamatergic transmission. Thus, a hypoglutamatergia, measured 
as a functional deficit of NMDA receptors, results in a hyperglutamatergia, 
measured as excitability of pyramidal neurons and excessive release of 
glutamate in cortical areas. As aforementioned, another issue to take into 
consideration is chronicity of the illness vs. duration of treatment with NMDA 
antagonists. In this regard, although the nature of some changes is similar 
following acute or protracted treatment with NMDA antagonists, and 
comparable with those occurring in early stages of schizophrenia, the duration 
of such changes after sustained administration seems to be more in accord with 
the persistence of clinical symptoms of the illness6. 
 
Neuropathological studies 
In recent years, postmortem studies have consistently evidenced alterations in 
the GABAergic system of schizophrenia patients22. These include 1) reduced 
levels of the mRNA encoding the 67-kDa isoform of glutamic acid 
decarboxylase (GAD67), the primary synthesizing enzyme for GABA; 2) 
reduction of the mRNA for the calcium-binding protein, parvalbumin (PV); 3) 
decreased immunoreactivity of the presynaptic GABA membrane transporter 
(GAT1) in chandelier axon cartridges; and 4) increased immunoreactivity for the 
GABAA 2 subunit in the postsynaptic axon initial segments of pyramidal 
neurons. PV interneurons regulate the oscillatory activity in the cerebral cortex, 
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and disruption of cortical oscillatory dynamics is postulated to underlie many of 
the neurocognitive deficits of schizophrenia. 
 Less attention has been paid to the presence of such changes after 
administration with NMDA receptor antagonists. In the animal setting, it is 
generally considered that sustained exposure to NMDA receptor antagonists is 
needed to produce a robust decrease of the expression of PV in the rat. In a 
recent study, however, we have found a reduction of PV mRNA expression in 
discrete corticolimbic regions (prefrontal cortex, hippocampal formation, 
amygdala)23 that have been implicated in schizophrenia. Further, the decrease 
of PV mRNA in the prefrontal cortex is limited to layers 3 and 5 (Figure 1), 
similar to what has been found in postmortem tissue of schizophrenia brain22. 
However, the lack of changes in GAD67 expression after acute NMDA 
blockade18 are at variance with human postmortem studies22, and would 
suggest that this enzyme isoform is rather involved in adaptive changes in 
development and maturation of GABA neurons. In fact, alterations in GAD67 
have been observed only when NMDA antagonists were administered early 
after birth or after repeated exposure. Overall, the similarity of changes in PV 
expression in schizophrenia and after NMDA administration adds construct 
validity to this animal model. 
 
Disconnectivity in the NMDA hypofunction model 
Over the last 30 years, evidence has emerged that schizophrenia can result 
from impairment in the connectivity between different areas of the brain rather 
than damage of particular areas. This would lead to a wrong processing of the 
information. Diffusion tensor imaging (DTI) studies have found abnormalities in 
white matter in frontal and temporal lobes in schizophrenia that correlated with 
the severity of psychotic symptoms24. These alterations are compatible with 
demyelinating processes. Interestingly, the myelination of white matter in 
humans starts postnatally and is completed in the adolescence/early adulthood, 
just the period of life when the first symptoms of schizophrenia usually appear. 
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The key role in the myelination process is played by oligodendrocytes and 
postmortem studies have reported a decrease in the number of 
oligodendrocytes in prefrontal cortex of subjects with schizophrenia25. 
 Although an association between NMDA hypofunction and impairment of 
the corpus callosum in schizophrenia has not been established unambiguously, 
a recent study has described that chronic ketamine consumption lead to 
abnormalities in frontal callosal fibers, similar to those present in schizophrenia 
patients26. Further research is needed to extend the knowledge of the effects of 
NMDA antagonists on the integrity of callosal fibers in the animal setting. In this 
regard, we have recently described that NMDA antagonists need to block 
NMDA receptors in both prefrontal cortices to produce the changes in prefrontal 
serotonergic and glutamatergic transmission27. Thus, our results support the 
hypothesis that a bilateral impairment of cortical inhibition in the medial 
prefrontal cortex is needed for noncompetitive NMDA antagonists to induce the 
state of cortical hyperactivity. It is possible that some of the alterations after 
NMDA antagonism observed in rodents (increase of cortical excitability, 
stereotypies) and in schizophrenia patients (distortion of reality, hallucinations, 
thought disorder) are caused by a disrupted cortico-cortical communication and 
the subsequent alterations in the processing of the information between 
hemispheres. 
 
Predictive validity of NMDA antagonism 
Predictive validity refers to the potential of a model to make adequate 
predictions about some measure. Nevertheless, in psychiatry, the term 
predictive validity is often limited to indicate the ability of the model to predict 
the therapeutic efficacy of new drugs in the human condition. In the clinical 
setting, psychosis caused by the administration of NMDA receptor antagonists 
has been shown to be attenuated by atypical (clozapine) rather than typical 
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(haloperidol) antipsychotic drugs6. In line with the lack of effect of typical 
antipsychotics on cognitive functions, it was observed that negative symptoms 
and cognitive deficits present in schizophrenia do not seem to result from an 
excessive dopaminergic transmission at D2 receptors. 
 In the animal setting, the effects of typical and atypical antipsychotic 
drugs may vary with regard to the experimental parameters measured. For 
instance, the NMDA receptor antagonist-induced hyperlocomotion and 
stereotypy is regarded as a surrogate for positive (psychotic) symptoms of 
schizophrenia, and has been associated with stimulation of dopamine 
transmission in striatum and nucleus accumbens. In contrast, deficits in 
executive and social functions as well as in working memory seem to rather 
model cognitive impairment in this illness. Both typical and atypical 
antipsychotic drugs are able to block the hyperlocomotion and stereotypies 
elicited by NMDA receptor antagonists. In a similar way, the expression of c-fos 
as well as the increase in pyramidal cell firing in prefrontal cortex evoked by 
NMDA receptor antagonists is also prevented by both clozapine and 
haloperidol. However, other experimental measures in preclinical studies 
appear to respond preferentially to atypical antipsychotic drugs. Thus, 
clozapine, but not haloperidol is able to attenuate the activation of glucose 
metabolism and the disruption of PPI induced by NMDA receptor antagonists28. 
Given that NMDA receptor antagonists cause a marked activation of the 
prefrontal cortex, it would be expected that drugs that reduce or prevent 
excessive prefrontal activation might be useful for treating positive and negative 
symptoms of schizophrenia12. In this regard, activation of mGlu2/3 receptors 
has been shown to produce improvements in both positive and negative 
symptoms of schizophrenia29. On the other hand, it appears that the excessive 
glutamatergic transmission after blockade of NMDA receptors is strongly 
dependent on dopamine D2 receptor activation, thereby being responsive to 
classical as well as atypical antipsychotics13. 
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 In our lab, we have found that NMDA receptor antagonists-induced 
increase in 5-HT transmission in the prefrontal cortex is prevented by local or 
systemic administration of atypical, but not typical, antipsychotic drugs13,30. 
Based on this observation, we have hypothesized that an excessive prefrontal 
5-HT transmission may be implicated in the negative symptoms and cognitive 
impairment in schizophrenia, for which atypical drugs seem to display superior 
efficacy. Although the number of drugs tested is low, our results suggest that 
increased prefrontal 5-HT release might be predictive of a better response to 
atypical antipsychotics. Antagonism at 5-HT2A and 1-adrenergic receptors as 
well as agonism at 5-HT1A receptors seems to play an important role in these 
effects25. Further research is needed to validate such prediction unequivocally. 
 
Conclusions 
 Given the difficulty of modeling schizophrenia as a whole, most recent 
approaches tend to recreate only specific symptoms associated with the illness. 
In this review, we have discussed some of the similarities and differences 
between NMDA receptor hypofunction and schizophrenia that have relevance to 
the human condition. Notably, the circuitry governing the different variables 
(cortical and subcortical neurotransmitter systems, stereotypical behavior) is 
distinct although overlapping. In the animal model, face validity rely on 
hyperlocomotion and stereotypies, a behavioral endpoint, which is not 
generated as a consequence of prefrontal function, and is regarded as a 
surrogate for the positive symptoms of schizophrenia. Construct validity of the 
animal model has remained elusive until one the most compelling findings in 
schizophrenia, i.e. a post-mortem reduction of the cortical expression of 
parvalbumin (PV), has been reproduced in rodents given acute or chronic 
NMDA receptor antagonists. However, the most difficult feature of NMDA 
hypofunction to model in rodents is transient nature of the drug effects, which 
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contrasts with the neurodevelopmental nature of schizophrenia. It would be 
conceivable that acute administration of NMDA receptor antagonists would lead 
to a reversible malfunctioning of PV-containing interneurons whereas in 
schizophrenia, a damage of these neurons takes place at early stages of 
neurodevelopment. In any event, the resulting abnormalities in central 
neurotransmitter systems and behavioral responses could bear some 
resemblance. 
 Finally, blockade of noncompetitive NMDA receptor antagonist-induced 
increases in locomotor activity is a key feature used in drug companies to 
discover novel antipsychotic drugs. In addition, we have proposed that blockade 
of the increase in cortical 5-HT transmission may be predictive of the 
“atypicality” of antipsychotic drugs. In summary, a better knowledge of the 
circuitry involved in mediating the various behavioral and neurochemical effects 
of NMDA receptor antagonists would likely increase the predictive utility of this 
model. 
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Figure Legend 
 
Figure 1. Expression of parvalbumin (PV) mRNA in the medial prefrontal cortex 
of the rat. (A) Low-magnification pseudocolored picture showing the 
distribution pattern of PV in a saline-injected rat. (B) High-magnification 
photomicrograph of the area delimited in (A) showing the predominant 
distribution of PV within layers 3 and 5 in the infralimbic region of the 
medial prefrontal cortex. (C) Reduced level of PV mRNA after 1 mg/kg of 
MK-801. (D) Bar graphs showing the mean ± SEM of PV mRNA of rats 
injected with saline or MK-801; *p < 0.05. Dashed line shows the 
localization of cerebral midline and Arabic numbers indicate the different 
cortical layers (note the absence of layer 4 in the medial prefrontal cortex 
of the rat). Scale bars: 2 mm in (A), and 600 µm in (B) and (C). 
